BCTXW
BriaCell Therapeutics Corp.Former ticker of BriaCell Therapeutics Corp. · BCTX stock page →
—
Market cap
$29.9M
Nano cap
1 year
−73.3%
from $13.34 · Oct 28
30 days
−14.4%
from $4.16
52-week range
$2.74–13.34
−73% from high · low Jun 11
Avg volume 20D
59.1K
shares / day
New fund stakes
0
Q2 2025 13F · 0 exits
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E May 22 FDA: BriaCell Presentations Highlight Positive Clinical Data fo…
- E May 26 FDA: BriaCell Receives Positive Recommendation from Data Safety…
- E May 31 Trial readout: Results Pending: SV-BR-1-GM (Phase 2) — Completed 68d ago
- E Jul 16 FDA: BriaCell Opens First Canadian Site – Sunnybrook – for Pivo…
- E Aug 5 FDA: BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Cl…
- E Sep 14 FDA: Data Safety Monitoring Board (DSMB) Recommends Continuing…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2025: 0 added (0 new), 1 trimmed or exited.
- TrendDOWNTREND
6% below its 50-day average.
Who's buying
13F· Q2 20250
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| UBS Group AG | NEAR_EXIT | $24.00 |
| UBS Group AG | TRIM | $274.00 |
| UBS Group AG | NEAR_EXIT | $1.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 14, 2026 FDA
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti
Jun 30, 2025 Inst.
UBS Group AG — NEAR_EXIT
314 shares ($24.00)
Mar 31, 2025 Inst.
UBS Group AG — TRIM
2,689 shares ($274.00)
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 14, 2026
FDA
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Sep 8, 2026
Contract
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Aug 24, 2026
Press release
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 24, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Aug 5, 2026
FDA
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Jul 16, 2026
FDA
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…